RANKL protein is expressed at the pannus–bone interface at sites of articular bone erosion in rheumatoid arthritis
The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: Receptor activator of NF-kappaB ligand (RANKL) and osteoprotegerin (OPG) have been demonstrated to be critical regulators of osteoclast generation and activity. In addition, RANKL has been implicated as an important mediator of bone erosion in rheumatoid arthritis (RA). However, the expression of RANKL and OPG at sites of pannus invasion into bone has not been examined. The present study was undertaken to further elucidate the contribution of this cytokine system to osteoclastogenesis and subsequent bone erosion in RA by examining the pattern of protein expression for RANKL, OPG and the receptor activator of NF-kappaB (RANK) in RA at sites of articular bone erosion. METHODS: Tissues from 20 surgical procedures from 17 patients with RA were collected as discarded materials. Six samples contained only synovium or tenosynovium remote from bone, four samples contained pannus-bone interface with adjacent synovium and 10 samples contained both synovium remote from bone and pannus-bone interface with adjacent synovium. Immunohistochemistry was used to characterize the cellular pattern of RANKL, RANK and OPG protein expression immediately adjacent to and remote from sites of bone erosion. RESULTS: Cellular expression of RANKL protein was relatively restricted in the bone microenvironment; staining was focal and confined largely to sites of osteoclast-mediated erosion at the pannus-bone interface and at sites of subchondral bone erosion. RANK-expressing osteoclast precursor cells were also present in these sites. OPG protein expression was observed in numerous cells in synovium remote from bone but was more limited at sites of bone erosion, especially in regions associated with RANKL expression. CONCLUSIONS: The pattern of RANKL and OPG expression and the presence of RANK-expressing osteoclast precursor cells at sites of bone erosion in RA contributes to the generation of a local microenvironment that favours osteoclast differentiation and activity. These data provide further evidence implicating RANKL in the pathogenesis of arthritis-induced joint destruction.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Activated T lymphocytes within arthritic joints have also been shown to express RANKL and therefore might contribute to the promotion of bone erosions (413, 416).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [416]
In the citing paper
“Activated T lymphocytes within arthritic joints have also been shown to express RANKL and therefore might contribute to the promotion of bone erosions (413, 416).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [416]
Citations
Cites
Arnett, F. C., Edworthy, S. M., Bloch, D. A., Mcshane, D. J., Fries, J. F., Cooper, N. S., Healey, L. A., Kaplan, S. R., Liang, M. H., Luthra, H. S., et al. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780310302 · Cited by 19,752 · cited 1×
“Tissue samples used in this study were collected as discarded material at the time of surgery from 20 surgical procedures from 17 patients, all of whom fulfilled the American College of Rheumatology (ACR) criteria for RA [34].”
MethodRevised Criteria for the Classification of Rheumatoid Arthritis
Arnett, F. C. (1990) · Orthopaedic Nursing · doi:10.1097/00006416-199003000-00011 · Cited by 7,723
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439 · cited 2×
“RANKL also stimulates osteoclast migration, fusion, activation and survival and thus acts at all stages of osteoclast generation and function [9, 13–16].”
BackgroundOsteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351 · cited 1×
“RANKL is an essential factor for osteoclastogenesis both in vitro and in vivo [9, 10].”
BackgroundKong, Y.-Y., Feige, U., Sarosi, I., Bolon, B., Tafuri, A., Morony, S., Capparelli, C., Li, J., Elliott, R., McCabe, S., et al. (1999) · Nature · doi:10.1038/46303 · Cited by 1,856 · cited 4×
“Recent studies investigating the pathogenic mechanisms of bone destruction in animal models of arthritis have provided substantial evidence that the osteoclast is the cell type primarily responsible for focal bone erosion, and that generation and activity of osteoclasts is dependent upon receptor activator of NF- B li…”
BackgroundInfluentialRANK is essential for osteoclast and lymph node development.
Dougall, W. C., Glaccum, M., Charrier, K., Rohrbach, K., Brasel, K., De Smedt, T., Daro, E., Smith, J., Tometsko, M. E., Maliszewski, C. R., et al. (1999) · Genes & Development · doi:10.1101/gad.13.18.2412 · Cited by 1,478 · cited 1×
“This cytokine stimulates precursor cells of the myeloid lineage to differentiate into osteoclasts by binding to its signalling receptor, receptor activator of NF-B (RANK) [ 11 , 12].”
BackgroundLam, J., Takeshita, S., Barker, J. E., Kanagawa, O., Ross, F. P., & Teitelbaum, S. L. (2000) · Journal of Clinical Investigation · doi:10.1172/jci11176 · Cited by 1,440 · cited 1×
“The pro-inflammatory cytokines TNF and interleukin (IL)-1 can regulate osteoclast differentiation and function in the presence of RANKL in vitro [44–49].”
BackgroundYasuda, H., Shima, N., Nakagawa, N., Mochizuki, S.-I., Yano, K., Fujise, N., Sato, Y., Goto, M., Yamaguchi, K., Kuriyama, M., et al. (1998) · Endocrinology · doi:10.1210/endo.139.3.5837 · Cited by 1,201 · cited 1×
“Osteoprotegerin (OPG) is a naturally occurring soluble decoy receptor for RANKL and effectively blocks the pro-osteoclastogenic action of RANKL at all stages of osteoclast generation and function [17–20].”
BackgroundHofbauer, L. C., Khosla, S., Dunstan, C. R., Lacey, D. L., Boyle, W. J., & Riggs, B. L. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.1.2 · Cited by 1,173 · cited 1×
“Cells of the osteoblast lineage can be induced to up-regulate RANKL production and down-regulate OPG production by pro-inflammatory cytokines known to be expressed in pannus tissues, including IL-1, TNF, parathyroid hormone-related peptide and others (reviewed in [62, 63]).”
Background
Research works printed but not linked: 3
- Gravallese, 2000, Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor, Arthritis Rheum, 43, 250, 10.1002/1529-0131(200002)43:2<250::aid-anr3>3.0.co;2-p · doi:10.1002/1529-0131(200002)43:2<250::aid-anr3>3.0.co;2-p
- Takayanagi, 2000, Involvement of receptor activator of nuclear factor kappa-B ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis, Arthritis Rheum, 43, 259, 10.1002/1529-0131(200002)43:2<259::aid-anr4>3.0.co;2-w · doi:10.1002/1529-0131(200002)43:2<259::aid-anr4>3.0.co;2-w
- Romas, 2000, Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis, Arthritis Rheum, 43, 821, 10.1002/1529-0131(200004)43:4<821::aid-anr12>3.0.co;2-t · doi:10.1002/1529-0131(200004)43:4<821::aid-anr12>3.0.co;2-t
Cited by
Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies
Guo, Q., Wang, Y., Xu, D., Nossent, J., Pavlos, N. J., & Xu, J. (2018) · Bone Research · doi:10.1038/s41413-018-0016-9 · Cited by 1,767
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G., & Tak, P. P. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.10.001 · Cited by 1,628
“…concentrations of RANKL in serum, synovial fluid or synovial tissue; however, reports differ as to whether OPG expression is increased or decreased in patients with RA (Feuerherm et al., 2001; Kotake et al., 2001; Ziolkowska et al., 2002; Catrina et al., 2006; Petit et al., 2006, Vis et al., 2006).”
BackgroundKearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Maeda, K., Kobayashi, Y., Udagawa, N., Uehara, S., Ishihara, A., Mizoguchi, T., Kikuchi, Y., Takada, I., Kato, S., Kani, S., et al. (2012) · Nature Medicine · doi:10.1038/nm.2653 · Cited by 542
“OPG expression was elevated in human synovial tissues and upregulated by tumor necrosis factor-α (TNF-α) in rheumatoid arthriti”
BackgroundNoss, E. H., & Brenner, M. B. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00648.x · Cited by 357
“Although which of these cells contributes more to osteoclast formation has been debated, a recent histological study of numerous RA bone erosions suggests that local production of RANKL by FLS in invading pannus tissue is critical (209).”
Background
Metadata
- Authors
- Pettit, A. R., Walsh, N. C., Manning, C., Goldring, S. R., & Gravallese, E. M.
- Affiliations
- The University of Queensland (AU)
- Beth Israel Deaconess Medical Center (US)
- Corresponding author
- Gravallese, E. M.
- Venue
- Rheumatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-02-20
- Volume
- 45
- Issue
- 9
- Pages
- 1068-1076
- ISSN
- 1462-0324 (ISSN-L)
- 1462-0332
- OpenAlex
- W2107773968
- Cited by
- 151
- References
- 66
- Citations by year
- 2025: 2 · 2024: 1 · 2023: 5 · 2022: 5 · 2021: 5 · 2020: 7 · 2019: 4 · 2018: 8 · 2017: 7 · 2016: 9 · 2015: 9 · 2014: 6 · 2013: 14 · 2012: 8
- FWCI
- 5.97
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Lara D. Veeken (publishedVersion)
- PubMed (publishedVersion)
- eScholarship@UMassChan (submittedVersion)
- Funders
- National Health and Medical Research Council
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01-AR-47665, R01AR047665)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Rheumatology › Osteoarthritis Treatment and Mechanisms
- Keywords
- RANKL, osteoprotegerin, RANK, rheumatoid arthritis, osteoclastogenesis, osteoclast precursor cells, synovium, subchondral bone erosion, joint destruction, RANKL/OPG system
- MeSH terms
- Adolescent, Adult, Arthritis, Rheumatoid, Bone Resorption, Carrier Proteins, Cell Differentiation, Child, Child, Preschool, Glycoproteins, Humans, Immunohistochemistry, Joints, Membrane Glycoproteins, Osteoclasts, Synovial Membrane, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Osteoprotegerin, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: RANKL protein is expressed at the pannus–bone interface at sites of articular bone erosion in rheumatoid arthritis. https://app.cochat.ai/papers/10.1093/rheumatology/kel045
- The paper
- Pettit, A. R., Walsh, N. C., Manning, C., Goldring, S. R., & Gravallese, E. M. (2006). RANKL protein is expressed at the pannus–bone interface at sites of articular bone erosion in rheumatoid arthritis. Rheumatology. https://doi.org/10.1093/rheumatology/kel045
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.